Publikationen, an denen er mitarbeitet José Alcamí Pertejo (44)

2023

  1. Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination

    Cancers, Vol. 15, Núm. 8

2022

  1. Early Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19

    Journal of Clinical Medicine, Vol. 11, Núm. 10

  2. Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection

    Journal of Clinical Medicine, Vol. 11, Núm. 8

  3. Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster

    Cancers, Vol. 14, Núm. 22

  4. Transcriptomic Evidence of the Immune Response Activation in Individuals With Limb Girdle Muscular Dystrophy Dominant 2 (LGMDD2) Contributes to Resistance to HIV-1 Infection

    Frontiers in Cell and Developmental Biology, Vol. 10

2021

  1. Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission

    Journal of Clinical Medicine, Vol. 10, Núm. 1, pp. 1-21

  2. Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU

    Frontiers in Immunology, Vol. 12

  3. Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity

    Frontiers in Immunology, Vol. 12

  4. Pharmacologic control of homeostatic and antigen-driven proliferation to target HIV-1 persistence

    Biochemical Pharmacology, Vol. 194

  5. Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy

    Biochemical Pharmacology, Vol. 192

2020

  1. Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection

    Biochemical Pharmacology, Vol. 182

  2. Dasatinib protects humanized mice from acute HIV-1 infection

    Biochemical Pharmacology, Vol. 174

2019

  1. HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study

    Scientific Reports, Vol. 9, Núm. 1

  2. The mutation of Transportin 3 gene that causes limb girdle muscular dystrophy 1F induces protection against HIV-1 infection

    PLoS Pathogens, Vol. 15, Núm. 8

  3. Tyrosine Kinase Inhibition: a New Perspective in the Fight against HIV

    Current HIV/AIDS Reports, Vol. 16, Núm. 5, pp. 414-422

2018

  1. Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors

    Biochemical Pharmacology, Vol. 156, pp. 248-264

  2. Factors leading to the loss of natural elite control of HIV-1 infection

    Journal of Virology, Vol. 92, Núm. 5

2017

  1. Changes in the cellular microRNA profile by the intracellular expression of HIV-1 Tat regulator: A potential mechanism for resistance to apoptosis and impaired proliferation in HIV-1 infected CD4+ T cells

    PLoS ONE, Vol. 12, Núm. 10

  2. Different expression of interferon-stimulated genes in response to HIV-1 infection in dendritic cells based on their maturation state

    Journal of Virology, Vol. 91, Núm. 8

  3. Potential role of tyrosine kinase inhibitors during primary HIV-1 infection

    Expert Review of Anti-Infective Therapy